Cogent Biosciences Inc
COGT9.350USD
+1.770+23.35%
收盘 07/07, 16:00（美东）报价延迟15分钟
1.06B总市值
亏损市盈率 TTM
关于 Cogent Biosciences Inc 公司
Cogent Biosciences, Inc. 是一家生物技术公司。该公司专注于开发针对基因定义疾病的精准疗法。该公司的临床项目贝祖卡斯替尼是一种选择性酪氨酸激酶抑制剂，旨在有效抑制 KIT D816V 突变以及 KIT 外显子 17 中的其他突变。KIT D816V 负责驱动系统性肥大细胞增多症，这是一种由肥大细胞不受控制的增殖引起的严重疾病。除了贝祖卡斯替尼，该公司还在开发一系列新型靶向疗法，以帮助患者对抗最初针对 FGFR2、ErbB2 和 PI3Kα 突变的严重基因驱动疾病。SUMMIT 是其针对非 AdvSM 患者的随机、全球、多中心、双盲、安慰剂对照、多部分 II 期临床试验。APEX 是一项开放标签、全球、多中心研究，评估贝祖卡斯替尼的安全性、有效性、药代动力学和药效学特征。
公司简介
公司代码COGT
公司名称Cogent Biosciences Inc
上市日期Mar 29, 2018
成立日期2014
CEOMr. Andrew Robbins
员工数量205
证券类型Ordinary Share
年结日Mar 29
公司地址275 Wyman Street
城市WALTHAM
上市交易所NASDAQ Global Select Consolidated
国家United States of America
邮编02451
电话16179455576
网址https://www.cogentbio.com/
公司代码COGT
上市日期Mar 29, 2018
成立日期2014
公司高管
名称
名称/职务
职务
持股
持股变动
Mr. Cole Pinnow
Mr. Cole Pinnow
Chief Commercial Officer
Chief Commercial Officer
45.85K
+3.15%
Mr. Evan D. Kearns, J.D.
Mr. Evan D. Kearns, J.D.
Chief Legal Officer, Corporate Secretary
Chief Legal Officer, Corporate Secretary
--
--
Mr. Matthew E. Ros
Mr. Matthew E. Ros
Independent Director
Independent Director
--
--
Dr. Karen Jean Ferrante, M.D.
Dr. Karen Jean Ferrante, M.D.
Independent Director
Independent Director
--
--
Mr. Todd E. Shegog
Mr. Todd E. Shegog
Independent Director
Independent Director
--
--
Dr. John Robinson, Ph.D.
Dr. John Robinson, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Mr. Peter Harwin
Mr. Peter Harwin
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. John L. Green
Mr. John L. Green
Chief Financial Officer
Chief Financial Officer
--
--
Ms. Arlene M. Morris
Ms. Arlene M. Morris
Independent Director
Independent Director
--
--
Mr. Andrew Robbins
Mr. Andrew Robbins
Chief Executive Officer, President, Director
Chief Executive Officer, President, Director
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Mr. Cole Pinnow
Mr. Cole Pinnow
Chief Commercial Officer
Chief Commercial Officer
45.85K
+3.15%
Mr. Evan D. Kearns, J.D.
Mr. Evan D. Kearns, J.D.
Chief Legal Officer, Corporate Secretary
Chief Legal Officer, Corporate Secretary
--
--
Mr. Matthew E. Ros
Mr. Matthew E. Ros
Independent Director
Independent Director
--
--
Dr. Karen Jean Ferrante, M.D.
Dr. Karen Jean Ferrante, M.D.
Independent Director
Independent Director
--
--
Mr. Todd E. Shegog
Mr. Todd E. Shegog
Independent Director
Independent Director
--
--
Dr. John Robinson, Ph.D.
Dr. John Robinson, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
收入明细
FY2021
暂无数据
地区USD
名称
营收
占比
United States
0.00
0.00%
业务
地区
暂无数据
股东统计
更新时间: 5月17日 周六
更新时间: 5月17日 周六
持股股东
股东类型
持股股东
持股股东
占比
Fidelity Management & Research Company LLC
12.45%
Kynam Capital Management LP
8.00%
Paradigm BioCapital Advisors LP
7.87%
Commodore Capital LP
7.81%
BlackRock Institutional Trust Company, N.A.
6.57%
Other
57.30%
持股股东
持股股东
占比
Fidelity Management & Research Company LLC
12.45%
Kynam Capital Management LP
8.00%
Paradigm BioCapital Advisors LP
7.87%
Commodore Capital LP
7.81%
BlackRock Institutional Trust Company, N.A.
6.57%
Other
57.30%
股东类型
持股股东
占比
Hedge Fund
47.38%
Investment Advisor
34.96%
Investment Advisor/Hedge Fund
22.22%
Venture Capital
8.74%
Research Firm
4.11%
Private Equity
0.82%
Pension Fund
0.28%
Bank and Trust
0.21%
Corporation
0.12%
机构持股
更新时间: 7月1日 周二
更新时间: 7月1日 周二
报告期
机构数
持股数
持股占比
持股变动
2025Q2
361
135.28M
118.82%
-6.42M
2025Q1
370
134.69M
118.30%
-7.69M
2024Q4
356
122.59M
107.82%
-16.59M
2024Q3
355
122.94M
112.32%
-17.94M
2024Q2
346
122.41M
127.95%
-6.37M
2024Q1
333
110.27M
115.27%
-1.77M
2023Q4
312
93.09M
108.04%
-6.98M
2023Q3
299
95.11M
113.69%
-5.31M
2023Q2
295
93.33M
133.52%
+4.32M
2023Q1
287
79.36M
115.42%
-7.30M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Fidelity Management & Research Company LLC
14.17M
12.45%
+198.56K
+1.42%
Mar 31, 2025
Kynam Capital Management LP
9.11M
8%
--
--
Mar 31, 2025
Paradigm BioCapital Advisors LP
8.96M
7.87%
+3.40M
+61.22%
Mar 31, 2025
Commodore Capital LP
8.89M
7.81%
+2.01M
+29.23%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
7.48M
6.57%
-85.44K
-1.13%
Mar 31, 2025
TCG Crossover Management, LLC
6.96M
6.12%
--
--
Apr 14, 2025
VR Adviser, LLC
6.38M
5.6%
+691.51K
+12.16%
Apr 14, 2025
Fairmount Funds Management LLC
6.23M
5.47%
--
--
Mar 31, 2025
The Vanguard Group, Inc.
6.04M
5.31%
-75.04K
-1.23%
Mar 31, 2025
Point72 Asset Management, L.P.
5.30M
4.65%
-51.76K
-0.97%
Mar 31, 2025
查看更多
持股ETF
更新时间: 7月6日 周日
更新时间: 7月6日 周日
机构名称
占比
Virtus LifeSci Biotech Clinical Trials ETF
0.93%
Tema Oncology ETF
0.92%
SPDR S&P Biotech ETF
0.17%
Direxion Daily S&P Biotech Bull 3X Shares
0.13%
iShares Micro-Cap ETF
0.11%
ProShares Ultra Nasdaq Biotechnology
0.09%
Invesco Nasdaq Biotechnology ETF
0.07%
Fidelity Enhanced Small Cap ETF
0.07%
iShares Biotechnology ETF
0.05%
iShares Russell 2000 Growth ETF
0.03%
查看更多
Virtus LifeSci Biotech Clinical Trials ETF
占比0.93%
Tema Oncology ETF
占比0.92%
SPDR S&P Biotech ETF
占比0.17%
Direxion Daily S&P Biotech Bull 3X Shares
占比0.13%
iShares Micro-Cap ETF
占比0.11%
ProShares Ultra Nasdaq Biotechnology
占比0.09%
Invesco Nasdaq Biotechnology ETF
占比0.07%
Fidelity Enhanced Small Cap ETF
占比0.07%
iShares Biotechnology ETF
占比0.05%
iShares Russell 2000 Growth ETF
占比0.03%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
Nov 06, 2020
Merger
4<1
Nov 06, 2020
Merger
4<1
Nov 06, 2020
Merger
4<1
Nov 06, 2020
Merger
4<1
公告日期
类型
比率
Nov 06, 2020
Merger
4<1
Nov 06, 2020
Merger
4<1
Nov 06, 2020
Merger
4<1
Nov 06, 2020
Merger
4<1
